Abstract. Promoter hypermethylation of tumor suppressor genes (TSGs) is a common feature of primary cancer cells. However, to date the somatic epigenetic events that occur in head and neck squamous cell carcinoma (HNSCC) tumorigenesis have not been well-defined. In the present study, we analyzed the promoter methylation status of the genes mutL homolog 1 (MLH1), Ras-association domain family member 1 (RASSF1A) and O-6-methylguanine-DNA methyltransferase (MGMT) in 23 HNSCC samples, three control tissues and one HNSCC cell line (UM-SCC 33) using methylation-specific PCR (MSP). The expression of the three proteins was quantified by semi-quantitative immunohistochemical analysis. The cell line was treated with the demethylating agent 5-azacytidine (5-Aza) and the methylation status after 5-Aza treatment was analyzed by MSP and DNA sequencing. Proliferation was determined by Alamar blue staining. We found that the MGMT promoter in 57% of the analyzed primary tumor samples and in the cell line was hypermethylated. The MLH promoter was found to be methylated in one out of 23 (4%) tumor samples while in the examined cell line the MLH promoter was unmethylated. The RASSF1A promoter showed methylation in 13% of the tumor samples and in the cell line. MGMT expression in the group of tumors with a hypermethylated promoter was statistically significantly lower compared to the group of tumors with no measured hypermethylation of the MGMT promoter. After treatment of the cell line with the demethylating agent 5-Aza no demethylation of the methylated MGMT and RASSF1A genes were determined by MSP. DNA sequencing verified the MSP results, however, increased numbers of unmethylated CpG islands in the promoter region of MGMT and RASSF1A were observed. Proliferation was significantly (p<0.05) reduced after treatment with 5-Aza. In summary, we have shown promoter hypermethylation of the MGMT and RASSF1A in HNSCC, suggesting that this epigenetic inactivation of TSGs may play a role in the development of HNSCC. 5-Aza application resulted in partial demethylation of the MGMT and RASSF1A TSGs and reduced proliferation of the tumor cells suggesting further evaluation of 5-Aza for HNSCC treatment.

Introduction

Head and neck squamous cell carcinoma (HNSCC) is a common neoplasm associated with exposure to tobacco and alcohol. It accounts for up to 5% of all newly diagnosed malignancies worldwide and is the sixth most common cancer in the world (1). The incidence of this type of tumor is expected to rise as a result of the increasing number of female and adolescent smokers. Despite considerable advances in diagnosis and treatment of HNSCC, the overall survival rate has remained constant at 60% over the past 30 years in the United States (2). The lack of progress in head and neck oncology emphasizes the need for basic studies on the molecular biology of HNSCC.

In HNSCC genetic analyses demonstrated the frequent loss of genomic material at several chromosomal loci suggesting the involvement of diverse tumor suppressor genes (TSGs) in the genesis of HNSCC (3,4). More recent, in addition to genetic alterations, promoter hypermethylation has been recognized as another mechanism of TSG inactivation. Accordingly, several studies have shown that methylation of CpG islands located within the promoter regions of tumor suppressor genes is a frequent event in the development of HNSCC and other human malignancies (5-7).
of hypermethylation by drugs in cancer patients, e.g., the efficiency of 5-azacytidine (5-Aza, Vidaza®) and decitabine (Dacogen®) are established for the therapy of acute myeloid leukemia and myelodysplastic syndromes (16,17).

Considering these findings, we examined the methylation status and the expression of MGMT, MLH1 and RASSF1A in 23 HNSCC biopsy samples and in one HNSCC cell line to establish a potential role of the hypermethylated TSGs in HNSCC development. Furthermore, we investigated the possibility of restoring the methylation status of the TSGs by treatment with 5-Aza and the functional impact of 5-Aza treatment on proliferation of the tumor cells.

Materials and methods

Patients and specimens. A total of 23 patients (19 males, 4 females) with histologically confirmed squamous cell carcinoma and one HNSCC cell line were included in this study (for patient and tumor characteristics see Table I). The specimens obtained in the operation room were fixed in formalin for 24 h, paraffin-embedded and used for later analysis. Clinical information was obtained from the patients charts. Patients ranged in age from 45 to 83 (mean age at operation 62). As controls, three samples of healthy gingiva were analyzed. This study was approved by the Institutional Review Board and performed in accordance to the actual version of the declaration of Helsinki. Informed consent was obtained. All patients were operated between March 2005 and April 2006 at the Department of Otorhinolaryngology, Head and Neck Surgery, University Medical Center of the Johannes Gutenberg University Mainz.

Cell culture. For our experiments the cell line UM-SCC 33 derived from squamous cell carcinoma of the head and neck (HNSCC) was used (Table I) (18,19).

The cell line was maintained in DMEM/Ham’s F12 (PAA), supplemented with 5% FCS (Greiner), and antibiotic solution (penicillin 100 U/ml and streptomycin 100 µg/ml, (PAA) at 37°C in 5% CO₂. The cell line was treated with 0.2 and 2 µM 5-Aza (Vidaza®) (Sigma-Aldrich) for 72 h.

DNA isolation and bisulfite modification. Genomic DNA was extracted using the DNeasy tissue kit (Qiagen) and 2 µg DNA each were subjected for bisulfite treatment (20). Bisulfite modification of genomic DNA converts unmethylated cytidine residues to uridine residues that are then converted to thymidine during subsequent PCR. We used the Epitect® Bisulfite kit (Qiagen). By the use of conversion specific primers during MSP-analysis the methylation status was then analyzed.

MSP (methylation specific PCR). Methylation in the region near the start codon of MGMT, MLH1 and RASSF1A was assessed using bisulfite-treated DNA. To increase the sensitivity and specificity we applied a two-step PCR approach. First, we amplified the TSG promoter regions with the primers and activity and specificity we applied a two-step PCR approach.

Table I. Patient, specimen and cell line characteristics.

| Patient no. | Age | Gender | Site               | TNM    |
|-------------|-----|--------|--------------------|--------|
| 1           | 54  | Male   | Larynx            | T3N0M0 |
| 2           | 68  | Male   | Oropharynx        | T1N0M0 |
| 3           | 52  | Female | Hypopharynx       | T2N2bM0|
| 4           | 70  | Male   | Floor of mouth    | T1N0M0 |
| 5           | 61  | Male   | Oropharynx        | T2N0M0 |
| 6           | 65  | Male   | Larynx            | T3N0M0 |
| 7           | 65  | Male   | Hypopharynx       | T2N2bM0|
| 8           | 58  | Female | Oropharynx        | T2N1M0 |
| 9           | 74  | Male   | Oropharynx        | T2N2cM0|
| 10          | 77  | Male   | Nasal sinus       | T2N0M0 |
| 11          | 46  | Male   | Oropharynx        | T2N1M0 |
| 12          | 45  | Male   | Oropharynx        | T3N0M0 |
| 13          | 63  | Male   | Hypopharynx       | T2N0M0 |
| 14          | 53  | Male   | Floor of mouth    | T3N0M0 |
| 15          | 51  | Male   | Oropharynx        | T2N2bM0|
| 16          | 64  | Male   | Oropharynx        | T4N2bM0|
| 17          | 67  | Male   | Tongue            | T4N0M0 |
| 18          | 65  | Male   | Larynx            | T3N0M0 |
| 19          | 61  | Male   | Oropharynx        | T1N1M0 |
| 20          | 61  | Male   | Larynx            | T1N0M0 |
| 21          | 67  | Female | Larynx            | T1N0M0 |
| 22          | 61  | Male   | Hypopharynx       | T3N2bM0|
| 23          | 83  | Female | Oropharynx        | T2N1M0 |
| Control no. |     |        |                   |        |
| 24          | NA  |        | Healthy gingiva   | -      |
| 25          | NA  |        | Healthy gingiva   | -      |
| 26          | NA  |        | Healthy gingiva   | -      |
| Cell line   |     |        |                   |        |
| UM-SCC 33   | Female | Nasal sinus | T4N3aM0 |

NA, not available.
(5'-GAG GAG GGG ATG AAG GAG G-3', upstream) and \textit{RASSF1A}-outer (5'-CTC CAA CCA AAT ACA ACC CT-3' downstream).

The PCR conditions were 95°C for 5 min; 40 cycles at 95°C for 30 sec, 53°C for 45 sec, and 72°C for 45 sec; and a final extension at 72°C for 10 min. Ten microliters of each sample was subjected to the second round of inner PCR amplified with the following MSP primers: for the \textit{MGMT} TSG, MSP-F (5'-TTT CGA CGT TCG TAG GTT TTC GC-3' upstream) and MSP-R (5'-GCA CTC TTC CGA AAA CGA AAC G-3', downstream) and unmethylated DNA-specific primers (UMSP), UMSP-F (5'-TTT GTG TTT TGA TGT TTG TAG GTT TT GT-3', upstream) and UMSP-R (5'-AAC TCC ACA CTC TTC CAA AAA CAA AAC A-3' downstream). For the \textit{MLH1} gene MSP analysis was performed with the following primers: MSP-F (5'-ACG TAG AGG ACC TAT TAG GGT CGT-3', upstream), MSP-R (5'-CCT CAT CGT AAC TAC CCG CG-3', downstream), UMSP-F (5'-TTT TGA TGT AGA GTG TGTT ATT AGG GTT GT-3', upstream) and UMSP-R (5'-ACC ACC TCA TCA TAA CTA CCC ACC A-3' downstream).

For the \textit{RASSF1A} gene inner PCR was performed with the following primers: MSP-F (5'-GGG TTT TGC GAG AGC ATT AGG GTT GT-3', upstream) and UMSP-F (5'-TTT CGA CGT TCG TAG GTT TTC GC-3' upstream) and unmethylated DNA-specific primers (UMSP), UMSP-F (5'-TTT CGA CGT TCG TAG GTT TTC GC-3' upstream) and UMSP-R (5'-GC TTA CAA AAG CAA ACC A-3' downstream).

The PCR conditions were 94°C for 15 min; 40 cycles at 94°C for 30 sec, 62°C for 30 sec, and 72°C for 30 sec; and a final extension at 72°C for 10 min. Primers for MSP and UMSP were as previously described (10,21,22). The sequences of the primers were derived from sequences AL 355531 (\textit{MGMT}), AC 002481 (\textit{RASSF1A}) and AB 017806 (\textit{MLH1}). The 81 bp and 93 bp PCR products of the \textit{MGMT} analysis as well as the 115 bp, 124 bp products of the \textit{MLH1} inner PCR and the 169 bp products of the \textit{RASSF1A} analysis, respectively, were separated by electrophoresis on a 2% agarose gel and stained with ethidium bromide. Distilled water was used as negative control. Bisulfite-treated lymphocyte DNA from healthy volunteers served as a positive control for unmethylated DNA. This DNA was methylated by the use of SssI methyltransferase (NEB) and used after bisulfite modification as a positive control for amplification of methylated DNA.

### DNA sequencing

The order of nucleotides in the promoter region of each gene were analyzed by DNA cycle-sequencing using the BigDye™ kit (ABI, Foster City, CA, USA). Briefly, extracted DNA samples from the cell line before and after treatment with 5-Aza have been modified with sodium bisulfit treatment. Amplification was performed by the use of M13 extended outer primers of MSP-analysis. Sequences were then determined using an ABI capillary sequencer 310.

### Immunohistochemistry

Immunohistochemical analysis of tumor samples was performed using standard procedures. In brief, formalin-fixed, paraffin-embedded tissues were used. Heat-induced antigen retrieval was performed using microwave treatment (3 times for 5 min each, 600 W in 10 mM citrate buffer, pH 6.0) of all slides after dewaxing and rehydration followed by blocking of endogenous peroxidase with 3% \(\text{H}_2\text{O}_2\)/methanol. Pre-incubation with 10% normal serum and 2% bovine albumin/PBS for 75 min to avoid unspecific binding, was followed by the incubation with the specific primary antibodies (\textit{MGMT}, 1:20 BD Pharmingen, NY; \textit{MLH1}, 1:20, BD Pharmingen; \textit{RASSF1A}, 1:50, Genway, CA) for 1 h at room temperature. The slides were consecutively incubated with biotinylated secondary antibody (goat-anti-mouse, 1:250, Dako A/S, Glostrup Denmark) for 45 min and then for 30 min with streptavidin-peroxidase. The visualization of the immunoreaction was performed with 3,3'-diaminobenzidine. All washing procedures were performed in PBS; dilutions of antibodies were prepared in 2% bovine albumin/PBS at room temperature. Negative controls were performed as previously described, substituting the primary antibody with PBS.

### Quantification of the expression

For evaluation of the \textit{MGMT}-expression in tumor samples we measured the stained area and intensity of each section in five fields by a computer-based image analysis method, previously described in detail by us (23). In brief, stainings were quantified by the multiplication of the stained area by the staining intensity and expressed as arbitrary units (A.U.).

\textit{Alamar blue assay-proliferation}. For determination of 5-Aza mediated functional consequences we incubated the cell line UM-SCC 33 for 72 h with 0.2 or 2 \(\mu\)M 5-Aza. Briefly, media were changed and 10% v/v Alamar Blue reagent (Biozol) was added to each well. The Alamar Blue® assay is based on a redox indicator, changing its color from blue (oxidized) to fluorescent red (reduced). After 4-h fluorescence was measured. Color changes are a measure of cellular metabolism, corresponding to the viability and proliferative activity of the cells (24). Each experiment was repeated three times.

### Statistics

A one-sided t-test was applied to assess the statistical significance. All calculations were performed using the SAS software, version 6.12 (Statistical Analysis Systems, SAS Institute Inc., Cary, NC, USA). \(p\)-values <0.05 are indicated.

### Results

To examine if the promoters of \textit{MGMT}, \textit{MLH1} and \textit{RASSF1A} in HNSCC are methylated, we analyzed these tumor suppressor genes for their methylation status in 23 samples of primary HNSCC and one HNSCC cell line by MSP (Table II). We found that the \textit{MGMT} promoter was methylated in 13 out of the 23 (57%) analyzed primary tumor samples and in the examined cell line. The \textit{MLH1} promoter was found to be methylated in one out of the 23 (4%) tumor samples while the \textit{MLH1} promoter in the UM-SCC cell line was unmethylated. MSP analysis of the \textit{RASSF1A} promoter showed promoter methylation in 3 out of 23 (13%) tumor samples and promoter methylation in the cell line (Table II). Fig. 1 shows representative examples of the MSP-analysis. To compare the methylation status, we additionally analyzed three samples of healthy gingiva by MSP-PCR. We found that in all three samples the promoter region of \textit{MLH1}, \textit{RASSF1A} and \textit{MGMT} was unmethylated. DNA sequencing verified the results of the MSP analysis in the UM-SCC 33 cell line. To analyze a possible association of hypermethylated promoter regions and
decreased expression levels, we quantified the MGMT-levels by semi-quantative immunohistochemical analysis.

MGMT expression varied from 478 to 3485 A.U. (mean 1.599±976 A.U.). MGMT expression statistically significantly (p<0.01) decreased in the tumor samples with a hypermethylated MGMT promoter region (Fig. 2). Due to limited tumor samples with hypermethylated RASSF1A and MLH1 promoter regions, no correlation analysis of hypermethylated promoter regions and expression levels was performed.

After treatment of the UM-SCC33 cell line with 5-Aza for 72 h we observed no demethylating effect by MSP analysis (representative result is shown in Fig. 3A). However, sequence analysis showed that 5-Aza treatment led to an increased number of unmethylated CpG islands in the methylated promoter region of RASSF1A in the UM-SCC33 cell line.

Table II. Analysis of RASSF1A, MLH1 and MGMT promoter methylation by MSP in primary HNSCC and cell lines and MGMT expression.

| Patient no. | RASSF1A methylation | MLH1 methylation | MGMT methylation | MGMT expression (A.U) |
|------------|---------------------|------------------|------------------|------------------------|
| 1 -        | -                   | -                | -                | 3286                   |
| 2 -        | -                   | -                | -                | 2596                   |
| 3 -        | -                   | -                | -                | 2788                   |
| 4 +        | -                   | -                | -                | NA                     |
| 5 -        | -                   | -                | -                | 1238                   |
| 6 -        | -                   | -                | +                | 3485                   |
| 7 -        | -                   | -                | +                | 2550                   |
| 8 -        | -                   | -                | +                | 1318                   |
| 9 -        | -                   | -                | +                | 532                    |
| 10 -       | -                   | -                | -                | 2818                   |
| 11 -       | -                   | -                | +                | 884                    |
| 12 -       | -                   | -                | +                | 1491                   |
| 13 -       | -                   | -                | +                | 709                    |
| 14 -       | -                   | -                | +                | 865                    |
| 15 -       | -                   | -                | +                | 1625                   |
| 16 -       | -                   | -                | +                | 478                    |
| 17 -       | -                   | -                | -                | 565                    |
| 18 +       | -                   | -                | +                | NA                     |
| 19 -       | +                   | -                | +                | 952                    |
| 20 +       | -                   | +                | -                | 1576                   |
| 21 -       | -                   | -                | +                | 617                    |
| 22 +       | -                   | -                | +                | NA                     |
| 23 +       | -                   | -                | +                | 1604                   |

| Control no. | RASSF1A methylation | MLH1 methylation | MGMT methylation | MGMT expression (A.U) |
|-------------|---------------------|------------------|------------------|------------------------|
| 24 -        | -                   | -                | -                | -                      |
| 25 -        | -                   | -                | -                | -                      |
| 26 -        | -                   | -                | -                | -                      |

| Cell line   | RASSF1A methylation | MLH1 methylation | MGMT methylation | MGMT expression (A.U) |
|-------------|---------------------|------------------|------------------|------------------------|
| UM-SCC 33  | -                   | -                | -                | -                      |

NA, not available; +, yes; -, no. A.U., arbitrary units.

Figure 1. Representative results of MSP analysis of RASSF1A, MGMT and MLH1 in biopsies obtained from primary tumors and cell lines. Bisulphite-modified DNA was amplified with primers specific for unmethylated (U) and methylated (M) DNA. Size of PCR products are 81 bp and 93 bp for MGMT, 115 bp and 124 bp for MLH1 and 169 bp for RASSF1A. Sample numbers are indicated above the bands and correspond to those of Table I. L, 100-bp ladder.
The MTT assay revealed a tendency for reduced tumor cell proliferation 4 h after treatment with 5-Aza for 72 h at a concentration of 0.2 µM (not significant) and a statistically significant reduction (p<0.05) of the proliferation at the same point of time with the 2 µM 5-Aza concentration (Fig. 4).

**Discussion**

Aberrations of genomic material as well as epigenetic modifications of genome-like promoter hypermethylations may result in the deregulation of tumor suppressor genes and finally in cancer (14). In HNSCC recurrent chromosomal losses have been described (3,4,14) suggesting the involvement of several tumor suppressor genes in the genesis of HNSCC. In this study we analyzed the methylation status of three potential TSGs. **MLH1** is a mismatch repair gene, located at 3p, a chromosomal arm showing high level of allelic losses in many cases of malignancies (9,12). Several studies reported deletion or hypermethylation of the gene in hereditary colon cancer, gastric, endometrium, prostate but also HNSCC cancer (21). The TSG **RASSF1A**, also located at 3p, plays a major role in the regulation of mitosis and it has been reported to be methylated in the vast majority of lung cancers and to a lesser extent in breast, ovarian and HNSCC cancer (8,11,22). **MGMT** is a TSG, located at 10q, playing vital roles in preventing induction of mutations and cancer related to alkylating agents (10,13). Aberrations of **MGMT** have been reported in lung, colon, brain, liver and HNSCC cancer (10).

We analyzed the methylation status of these three TSGs in tumor samples from 23 patients with HNSCC and in one cell line by MSP PCR. We found that the **MLH1** promoter was methylated in one tumor (4%) while no methylation could be observed in the cell line.

A direct association between hypermethylation of **MLH1** and cancer has been reported in colon cancer but reports on the methylation status of the same gene in HNSCC are inconclusive and have ranged from 0 to 88%. High percentage (88%) of **MLH1** methylation was reported by Liu et al but only in samples previously found to have loss of expression of the gene product (25). Steinmann et al reported that 69% of the 54 HNSCC samples showed hypermethylation of the **MLH1** promoter (26), while two studies with 96 and 57 samples did not find methylation at all (27,28). Thus, our results concerning the **MLH1** promoter methylation are in agreement with other reports. The widely divergent findings reported in the literature may be attributed to different sensitivities of the techniques as well as to insufficient DNA quality because of tissue preservation or bisulfite treatment. Furthermore, Wright and Stewart argued the importance of histological grading for **MLH1** expression, reporting that a high sample number (70%) lacked **MLH1** expression in poorly differentiated colon adenocarcinoma. Thus, the reported **MLH1** methylation status may also depend on the variety of the histological grading of a study group in HNSCC (29). Yamamoto et al reported a high risk of developing secondary carcinoma in the gastrointestinal tract, in patients with defective protein expression of **MLH1** (30), while in a further study
a significant correlation between the methylation of mismatch repair genes and multiple oral malignancies was found (31). Since our patient cohort consisted from patients with solitary tumors, that could be a further reason for the very rare MLH1 methylation reported in our study. Taken together, the above data suggest that aberrant MLH1 methylation-mediated transcriptional silencing might play a role in the development of multiple synchronous or metachronous malignancies, but it may be of minor importance for the development of solitary HNSCC lesions.

The methylation of the RASSF1A promoter was also rare in 3 out of 23 (13%) tumor samples while the RASSF1A promoter was found methylated in the UM-SCC 33 cell line. These results are in accordance to the study of Dong et al who reported of RASSF1A methylation in 15% of primary HNSCC and higher frequency in cell lines (32) and to Hogg et al who reported of 17% RASSF1A methylation in HNSCC while poorly differentiated HNSCC were more commonly methylated for RASSF1A than moderately and well differentiated HNSCC (8). Steimann et al also report of 18% RASSF1A methylation in an analysis of 54 HNSCC tumor samples (26). Notably, Lo et al have reported 14 of 21 primary nasopharyngeal carcinomas to show RASSF1A promoter methylation (33). This difference in the prevalence of the RASSF1A methylation may reflect the known differences in the disease. Hence epigenetic inactivation of RASSF1A plays an important role in the development of cancer but is apparently less important in HNSCC where genes other than RASSF1A may be of greater importance.

The MGMT TSG was found in 13 out of the 23 (57%) analyzed primary tumor samples as well as in the examined cell line methylated. Accordingly, we found statistically significantly decreased protein levels of MGMT in the hypermethylated tumors. In the literature the incidence of MGMT promoter hypermethylation in HNSCC ranged from 18% to 54% (26,34,35). Frequent MGMT methylation can increase the sensitivity towards the mutagenic effects of DNA alkylating chemotherapeutics in patients with malignant astrocytomas, glioma and diffuse large B-cell lymphoma (36,37).

In gastric cancer it has been previously reported that a correlation between MGMT methylation and lymph node metastasis exists (38). It can be hypothesized that in HNSCC the epigenetic loss of MGMT function may increase the mutation rates as a result of an impaired repair of DNA damage induced by cigarette smoke nitrosamines. On the other hand, it can facilitate the cytotoxic effects of DNA alkylating chemotherapies in patients with malignant astrocytomas, glioma and diffuse large B-cell lymphoma (36,37).

In gastric cancer it has been previously reported that a correlation between MGMT methylation and lymph node metastasis exists (38). It can be hypothesized that in HNSCC the epigenetic loss of MGMT function may increase the mutation rates as a result of an impaired repair of DNA damage induced by cigarette smoke nitrosamines. On the other hand, it can facilitate the cytotoxic effects of DNA alkylating chemotherapies in patients with malignant astrocytomas, glioma and diffuse large B-cell lymphoma (36,37).

Acknowledgements

We are greatly indebted to Bettina Mros for her excellent technical assistance. This study was funded by a grant provided by the Foundation Tumour Research Head and Neck, Wiesbaden, Germany. The foundation is a non-profit organization. The funders played no role in the experiment design, execution, analysis or preparation of the study.

References

1. Vokes EE, Weichselbaum RR, Lippman SM and Hong WK: Head and neck cancer: N Engl J Med 328: 184-194, 1993.
2. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics. CA Cancer J Clin 60: 277-300, 2010.
3. Gollin SM: Chromosomal alterations in squamous cell carcinomas of the head and neck: window to the biology of disease. Head Neck 23: 238-253, 2001.
4. Brieger J, Jacob R, Riazimand HS, Essig E, Heinrich UR, Bittinger F and Mann WJ: Chromosomal aberrations in premalignant and malignant squamous epithelium. Cancer Genet Cytogenet 144: 148-155, 2003.
5. Ha PK and Califano JA: Promoter methylation and inactivation of tumour suppressor genes in oral squamous cell carcinoma. Lancet Oncol 7: 77-82, 2006.
6. Esteller M, Corin PG, Baylin SB and Herman JG: A gene hypermethylation profile of human cancer. Cancer Res 61: 3225-3229, 2001.
7. Brieger J, Pongsapich W, Mann SA, Hedrich J, Fruth K, Pogożelski B and Mann WJ: Demethylation treatment restores PDCD4 expression and impairs aggressiveness of head and neck squamous cell carcinoma. Oral Oncol 46: 678-683, 2010.
8. Hogg RP, Honorio S, Martinez A, Agathanggelou A, Dallol A, Fullwood P, Weichselbaum R, Kuo MJ, Maher ER and Latif F: Frequent 3p allele loss and epigenetic inactivation of the RASSF1A tumor suppressor gene from region 3p21.3 in head and neck squamous cell carcinoma. Eur J Cancer 38: 1585-1592, 2002.

9. Viswanathan M, Tsichuda N and Shannagum G: Promoter hypermethylation profile of tumor-associated genes p16, p15, hMLH1, MGMT and E-cadherin in oral squamous cell carcinoma. Int J Cancer 105: 41-47, 2003.

10. Kato K, Ikeda K, Kudo T, Mori H, Yamashita T, Toida M and Shibata T: Aberrant promoter hypermethylation of p16 and MGMT genes in oral squamous cell carcinomas and the surrounding normal mucosa. J Cancer Res Clin Oncol 132: 735-743, 2006.

11. van der Weyden L, Tachibana KK, Gonzalez MA, Adams DJ, Ng BL, Petty R, Venkitaraman AR, Arends MJ and Bradley A: The RASSF1A isofrom of RASSF1 promotes microtubule stability and suppresses tumorigenesis. Mol Cell Biol 25: 8356-8367, 2005.

12. Jiricny J and Nystrom-Lahti M: Mismatch repair defects in cancer. Curr Opin Genet Dev 10: 157-161, 2000.

13. Pegg AE: Mammalian O6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res 50: 6119-6129, 1990.

14. Baylin SB, Esteller M, Rountree MR, Bachman KE, Schuebel K and Herman JG: Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet 10: 687-692, 2001.

15. Belinsky SA, Liechty KC, Gentry FD, Wolf HJ, Rogers J, Vu K, Haney J, Kennedy TC, Hirsch FR, Miller Y, et al: Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. Cancer Res 66: 3338-3344, 2006.

16. Daskalakis M, Nguyen TT, Nguyen C, Guldberg P, Kohler G, Wijermans P, Weichselbaum R, Kuo MJ, Maher ER and Latif F: Hypermethylation of RASSF1A in gastric cancer cell lines by combined treatment of 5-Aza-CdR and NaB. World J Gastroenterol 12: 3338-3344, 2006.

17. Ruter B, Wijermans PW and Lubbert M: DNA methylation as a therapeutic target in hematologic disorders: recent results in older patients with myelodysplasia and acute myeloid leukaemia. Int J Hematol 80: 128-135, 2004.

18. Welkowski HY, Jacob R, Riazimand SH, Bernauer HS and Mann WJ: Molecular biologic characteristics of seven new cell lines of squamous cell carcinomas of the head and neck and comparison to fresh tumor tissue. Oncology 65: 60-71, 2003.

19. Lin CJ, Grandis JR, Carey TE, Gollin SM, Whiteside TL, Koch WM, Ferris RL and Lai SY: Head and neck squamous cell carcinoma cell lines of squamous cell carcinomas of the head and neck and malignant phenotype suppression. J Natl Cancer Inst 93: 3150-3154, 2001.

20. Herman JG, Graff JR, Carey TE, Gollin SM, Whiteside TL, Koch WM, Ferris RL and Lai SY: Head and neck squamous cell carcinoma cell lines: established models and rationale for selection. Head Neck 29: 163-188, 2007.

21. Herman JG, Graff JR, Myöhänen S, Spink BD and Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93: 9821-9826, 1996.

22. Nan HM, Song YJ, Yun HY, Park JS and Kim H: Effects of dietary intake and genetic factors on hypermethylation of the hMLH1 gene promoter in gastric cancer. World J Gastroenterol 11: 3834-3841, 2005.

23. Barbuc DG, Forgacs E, Zöchbauer-Müller S, Shivakumar L, Fong K, Gao B, Randle D, Kondo M, Virmani A, Bader S, et al: Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst 93: 699-699, 2001.

24. Gosepath J, Brieger J, Lehr HA and Mann WJ: Expression, localization and significance of vascular permeability/vascular endothelial growth factor in nasal polyps. Am J Rhinol 19: 7-13, 2005.

25. Ahmed SA, Gogal RM and Walsh JE: A new rapid and simple non-radioactive assay to monitor and determine the proliferation of lymphocytes: an alternative to [3H]thymidine incorporation assay. J Immunol Methods 170: 211-224, 1994.

26. Liu K, Zuo C, Luo QK, Suen JY, Hanna E and Fan CY: Promoter hypermethylation and inactivation of hMLH1. A DNA mismatch repair gene, in head and neck squamous cell carcinoma. Diagn Mol Pathol 12: 50-56, 2003.